Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...

Request To Download Free Sample of This Strategic Report @- https://reportocean.com/industry-verticals/sample-request?report_id=Pol1398 ...

Building on the solid performance of 2024, Grifols (GRFS) forecasts continued success in 2025 with anticipated revenue growth and EBITDA expansion. Excluding the impact of the Part D redesign ...

It's time for an update on the Medical company Grifols, S.A. (NASDAQ:GRFS). It's been about 4 months since I last updated on the business, with that update being specific to an event where ...

The company said, “Building on the solid performance of 2024, Grifols (GRFS) forecasts continued success in 2025 with anticipated revenue growth and EBITDA expansion. Excluding the impact of the ...

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ ... term "defensive" a step further than practically any other industry. Improvements in medical technology, medications, ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the ...

Spanish drugmaker Grifols GRFS-Q said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 ...

Grifols reported a 13.6% increase in Q4 revenues year-on-year. The company's leverage ratio improved, decreasing from 6.8x in Q1 to 4.6x by year-end. Innovation milestones for 2024 were ...